Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cardiology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cardiology Other
    The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials - (BMJ)
    FDA Approves Dronedarone for Atrial Fibrillation or Atrial Flutter - (DGNews)
    Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease - (JAMA)
    Novel and conventional biomarkers for prediction of incident cardiovascular events in the community - (JAMA)
    Kidney function and risk of cardiovascular disease and mortality in women: a prospective cohort study - (BMJ)

    News archive

     Recent webcasts/CME - Cardiology Other
    • State of the Science in Managing the Treatment-Experienced Patient With HIV
    • What's New in Managing Treatment-Experienced Patients With HIV?
    • Applying Data to Practice: Case Vignettes
    • Rheumatoid Arthritis: The Heart of the Matter Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis
      Supraventricular Tachycardia in Children and Adolescents

      Webcasts/CME archive

       Recent cases - Cardiology Other
        Cardiogenic Shock Caused by Disulfiram
        Congenital Atresia of the Left Main Coronary Artery Associated With Patent Ductus Arteriosus and Aortic Regurgitation
        Pleural Effusion and Pulmonary Hypertension in a Patient With Parkinson Disease Treated With Cabergoline
        A Well-Circumscribed Density Along the Right Heart Border
        A Case of Massive Pulmonary Embolism with ST Elevation in Leads V1-4

        Cases archive
          




        my personal edition > cardiology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Coenzyme Q10 Lessens Muscle-Related Side Effects in Patients on Statins: Presented at ACC

        By Jill Stein

        ORLANDO, FL -- March 7, 2005 -- Patients with significant myopathy who are taking statin therapy have a significant decrease in myopathic pain after 30 days of supplementation with coenzyme Q10, according to results presented here on March 6th at the American College of Cardiology 54th Annual Scientific Session.

        Patricia Kelly, DO, Associate Professor of Medicine, University Hospital Medial Center, Stony Brook, New York, United States, randomized in a double-blind design 41 statin-treated patients with myopathic pain to 30 days of supplementation with 400 IU of vitamin E or 100 mg daily of coenzyme Q10.

        "Statin treatment markedly reduces [the incidence of] cardiac events and mortality," Dr. Kelly said. "However, the reported side effects of treatment include myopathy, muscle damage associated with increased levels of creatinine phosphokinase, and abnormalities of liver function."

        The researchers conducted the present trial to determine if coenzyme Q10 supplementation would improve muscle related adverse effects in patients on statins. "If coenzyme Q10 supplementation were effective in reducing the symptoms of myopathy associated with statin use, it would be possible for patients to retain the beneficial effects of cholesterol lowering while reducing significant side effects," she added.

        The two treatment groups were similar with respect to demographic and clinical parameters.

        Pre- and post- vitamin E, pain remained unchanged (3.9 versus 4.4, P = NS). Pre- and post coenzyme Q10, pain improved significantly (6.2 1.7 versus 3.1, P <.001).

        Pain improved in three of 20 vitamin E patients and 18 of 21 coenzyme Q 10 patients (P <.001).

        There was no significant change in creatinine phosphokinase with treatment in either group nor did these levels correlate with pain severity.

        Coenzyme Q10 did not have any effect on lipid levels and was safe and well tolerated.

        "This study provides encouraging evidence for the use of coenzymeQ10 in alleviating myopathic pain in patients taking statins," Dr. Kelly said.

        Study strengths include the 100% compliance rates, randomized blinded design, use of validated pain scale, and duration of treatment of 4 weeks to ensure adequate absorption of coenzyme Q10, she added.


        [Presentation title: Coenzyme Q10 Improves Myopathic Pain in Statin-Treated Patients. Abstract 1001-117]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send